Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet Oncology.[1] …
Continue reading →
Among women with ovarian cancer, those who have a BRCA2 gene mutation may have a better response to chemotherapy and longer survival than those who do not have a BRCA gene mutation. These results were published in the Journal of the American Medical Association. Inherited mutations in two genes—BRCA1 and BRCA2—have been found to greatly [...]
According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
In a study that evaluated two generations of women with BRCA1 or BRCA2 mutations, breast and ovarian cancers tended to be diagnosed at a younger age in the later generation. These results were published in Cancer. Inherited mutations in two genes—BRCA1 and BRCA2—have been found to greatly increase the lifetime risk of developing breast and [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
Postmenopausal women who use hormone therapy (HT) may have a 29% increased risk of developing ovarian cancer. These findings were presented at the Ninth Annual American Association for Cancer Research Frontiers in Cancer Prevention Research Conference. Hormone therapy using estrogen, with or without progestin, is an effective treatment for many menopausal symptoms. During the last [...]
DPX-Survivac—an investigational vaccine designed to prompt an immune response against cancer cells—will undergo Phase I/II testing in patients with ovarian cancer. This announcement was made by one of the companies involved in developing the vaccine. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer death [...]
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does reduce recurrence of brain metastases. These findings were recently published in the Journal of Clinical Oncology.[1] One common [...]
Among women with newly diagnosed, advanced ovarian cancer, treatment with Hycamtin® (topotecan) and cisplatin prior to standard chemotherapy increases side effects and does not improve progression-free survival. These results were published in the Journal of the National Cancer Institute. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading [...]
In a Phase II clinical trial among women with recurrent ovarian cancer, the investigational targeted therapy AMG 386 produced promising response rates when used in combination with paclitaxel. These results were presented at the 35th European Society for Medical Oncology (ESMO) Congress. Many women treated for ovarian cancer will eventually experience a recurrence of their [...]
